MET and cancer: While the prevalent strategy in drug discovery is “one drug, one target”, the realization that many drugs exerts their effect through more than one target have led to the increased interest in designed multiple ligands (DML).12,13 Well-designed DMLs can reduce drug–drug interactions and side effects, and simplify drug pharmacokinetics.14,15 In search of novel treatment strategies for cancer, we aim to develop dual inhibitors of MET and WNT signaling.